{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:33:10Z","timestamp":1794317590853,"version":"4.9.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"Importance<\/jats:title>In older patients with atrial fibrillation who take anticoagulants for stroke prevention, bleeding is increased compared with younger patients, thus, clinicians frequently prescribe lower than recommended doses in older patients despite limited randomized data.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate ischemic and bleeding outcomes in patients 80 years and older with atrial fibrillation receiving edoxaban, 60 mg vs 30 mg, and edoxaban, 30 mg vs warfarin.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation\u2013Thrombolysis in Myocardial Infarction 48) was a parallel-design, double-blind, global clinical trial that randomized patients with atrial fibrillation to either one of 2 edoxaban dosing regimens or warfarin. This secondary analysis focused on patients 80 years or older without dose-reduction criteria receiving edoxaban, 60 mg vs 30 mg, as well as patients with or without dose-reduction criteria receiving edoxaban, 30 mg, vs warfarin. Study data were analyzed between October 2022 and December 2023.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Oral edoxaban, 30 mg once daily; edoxaban, 60 mg once daily; or warfarin.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Primary net clinical outcome of death, stroke or systemic embolism, and major bleeding and each individual component.<\/jats:p><\/jats:sec>Results<\/jats:title>The current analysis included 2966 patients 80 years and older (mean [SD] age, 83 [2.7] years; 1671 male [56%]). Among 1138 patients 80 years and older without dose-reduction criteria, those receiving edoxaban, 60 mg vs 30 mg, had more major bleeding events (hazard ratio [HR], 1.57; 95% CI, 1.04-2.38; P<\/jats:italic>\u2009=\u2009.03), particularly gastrointestinal hemorrhage (HR, 2.24; 95% CI, 1.29-3.90; P<\/jats:italic>\u2009=\u2009.004), with no significant difference in efficacy end points. Findings were supported by analyses of endogenous factor Xa inhibition, a marker of anticoagulant effect, which was comparable between younger patients receiving edoxaban, 60 mg, and older patients receiving edoxaban, 30 mg. In 2406 patients 80 years and older with or without dose-reduction criteria, patients receiving edoxaban, 30 mg, vs warfarin had lower rates of the primary net clinical outcome (HR, 0.78; 95% CI, 0.68-0.91; P<\/jats:italic>\u2009=\u2009.001), major bleeding (HR, 0.59; 95% CI, 0.45-0.77; P<\/jats:italic>\u2009&amp;lt;\u2009.001), and death (HR, 0.83; 95% CI, 0.70-1.00; P<\/jats:italic>\u2009=\u2009.046), whereas rates of stroke or systemic embolism were comparable.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial, in patients 80 years and older with atrial fibrillation, major bleeding events were lower in patients randomized to receive edoxaban, 30 mg per day, compared with either edoxaban, 60 mg per day (in patients without dose-reduction criteria), or warfarin (irrespective of dose-reduction status), without an offsetting increase in ischemic events. These data support the concept that lower-dose anticoagulants, such as edoxaban, 30 mg, may be considered in older patients with atrial fibrillation even in the absence of dose-reduction criteria.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT00781391<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2024.1793","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T15:05:16Z","timestamp":1720623916000},"page":"817","source":"Crossref","is-referenced-by-count":34,"title":["Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation"],"prefix":"10.1001","volume":"9","author":[{"given":"Andr\u00e9","family":"Zimerman","sequence":"first","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Steffel","sequence":"additional","affiliation":[{"name":"University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas M.","family":"Van Mieghem","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus University Medical Center, Thoraxcenter, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Palazzolo","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy Zi Li","family":"Chen","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Pharma Development, Edison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Unverdorben","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Pharma Development, Edison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T.","family":"Ruff","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott M.","family":"Antman","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"hoi240036r1","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1093\/eurheartj\/suab150","article-title":"Non\u2013vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation.","volume":"24","author":"Giugliano","year":"2022","journal-title":"Eur Heart J Suppl"},{"issue":"23","key":"hoi240036r2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017024","article-title":"Management of atrial fibrillation in older patients by morbidity burden: insights from Get With The Guidelines\u2013Atrial Fibrillation.","volume":"9","author":"Dalgaard","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"hoi240036r3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial.","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"hoi240036r4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/ehjcvp\/pvz061","article-title":"Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial.","volume":"6","author":"Nicolau","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"hoi240036r5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ahj.2021.01.013","article-title":"Edoxaban vs warfarin in patients with atrial fibrillation in relation to the risk of stroke: a secondary analysis of the ENGAGE AF-TIMI 48 study.","volume":"235","author":"de Groot","year":"2021","journal-title":"Am Heart J"},{"issue":"11","key":"hoi240036r6","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jacc.2016.06.034","article-title":"Edoxaban vs Warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis.","volume":"68","author":"Steffel","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"hoi240036r7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ahj.2021.12.017","article-title":"Edoxaban vs warfarin in high-risk patients with atrial fibrillation: a comprehensive analysis of high-risk subgroups.","volume":"247","author":"Gencer","year":"2022","journal-title":"Am Heart J"},{"issue":"12","key":"hoi240036r8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jacc.2020.07.045","article-title":"Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants.","volume":"76","author":"Camm","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"hoi240036r9","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non\u2013vitamin k antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry.","volume":"68","author":"Steinberg","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi240036r10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jjcc.2022.03.006","article-title":"Trends of anticoagulant use and outcomes of patients with nonvalvular atrial fibrillation: findings from the RAFFINE registry.","volume":"80","author":"Miyazaki","year":"2022","journal-title":"J Cardiol"},{"issue":"11","key":"hoi240036r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.42964","article-title":"Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010-2020.","volume":"5","author":"Ko","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"22","key":"hoi240036r12","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban vs warfarin in patients with atrial fibrillation.","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"hoi240036r13","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.jacc.2020.12.053","article-title":"Randomized, double-blind comparison of half-dose vs full-dose edoxaban in 14?014 patients with atrial fibrillation.","volume":"77","author":"Steffel","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"hoi240036r14","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation.","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"hoi240036r15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.","volume":"5","author":"Kato","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"hoi240036r16","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1161\/CIRCULATIONAHA.118.033933","article-title":"Linking endogenous factor Xa Activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentrations and clinical outcomes in the ENGAGE AF-TIMI 48 trial.","volume":"138","author":"Yin","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"hoi240036r17","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non\u2013vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"issue":"4","key":"hoi240036r18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","article-title":"Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation\u2014Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).","volume":"160","author":"Ruff","year":"2010","journal-title":"Am Heart J"},{"issue":"4","key":"hoi240036r19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients.","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"9984","key":"hoi240036r20","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti\u2013factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"hoi240036r21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1309\/AJCPR3JTOK7NKDBJ","article-title":"Pathology consultation on anticoagulation monitoring: factor X\u2013related assays.","volume":"140","author":"Wool","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"23","key":"hoi240036r22","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban vs vitamin K antagonist for atrial fibrillation after TAVR.","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"hoi240036r23","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban vs warfarin in patients with atrial fibrillation.","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"hoi240036r24","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation.","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"hoi240036r25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.arr.2018.10.006","article-title":"Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation.","volume":"49","author":"Kato","year":"2019","journal-title":"Ageing Res Rev"},{"issue":"21","key":"hoi240036r26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029865","article-title":"Benefits and harms of standard vs reduced-dose direct oral anticoagulant therapy for older adults with multiple morbidities and atrial fibrillation.","volume":"12","author":"Hayes","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"hoi240036r27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1056\/NEJMoa022831","article-title":"Acquired von Willebrand syndrome in aortic stenosis.","volume":"349","author":"Vincentelli","year":"2003","journal-title":"N Engl J Med"},{"issue":"15","key":"hoi240036r28","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/archinte.163.15.1821","article-title":"Increased prevalence of aortic stenosis in patients with arteriovenous malformations of the gastrointestinal tract in Heyde syndrome.","volume":"163","author":"Batur","year":"2003","journal-title":"Arch Intern Med"},{"issue":"5","key":"hoi240036r29","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.3390\/jcm12051870","article-title":"Prescribing patterns and outcomes of edoxaban in atrial fibrillation: 1-year data from the Global ETNA-AF Program.","volume":"12","author":"Chao","year":"2023","journal-title":"J Clin Med"},{"issue":"FI1","key":"hoi240036r30","doi-asserted-by":"publisher","first-page":"f30","DOI":"10.1093\/ehjcvp\/pvaa079","article-title":"Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.","volume":"7","author":"de Groot","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"12","key":"hoi240036r31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.121.007971","article-title":"Off-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis.","volume":"14","author":"Zhang","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"hoi240036r32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijcard.2022.04.062","article-title":"Clinical effects of off-label reduced doses of direct oral anticoagulants: a systematic review and meta-analysis.","volume":"362","author":"Pereira","year":"2022","journal-title":"Int J Cardiol"},{"issue":"8","key":"hoi240036r33","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.amjmed.2016.02.028","article-title":"Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: insights from the ENGAGE AF-TIMI 48 trial.","volume":"129","author":"Giugliano","year":"2016","journal-title":"Am J Med"},{"key":"hoi240036r34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijcard.2018.01.065","article-title":"Clinical events after interruption of anticoagulation in patients with atrial fibrillation: an analysis from the ENGAGE AF-TIMI 48 trial.","volume":"257","author":"Cavallari","year":"2018","journal-title":"Int J Cardiol"},{"issue":"10","key":"hoi240036r35","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2016.101","article-title":"Precision medicine in cardiology.","volume":"13","author":"Antman","year":"2016","journal-title":"Nat Rev Cardiol"},{"issue":"13","key":"hoi240036r36","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges.","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"hoi240036r37","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.cjca.2015.09.023","article-title":"Values and preferences of physicians and patients with nonvalvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention.","volume":"32","author":"Andrade","year":"2016","journal-title":"Can J Cardiol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2820443\/jamacardiology_zimerman_2024_oi_240036_1725982864.01018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T15:42:43Z","timestamp":1726069363000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2820443"}},"subtitle":["Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2024.1793","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}